Poster Listing

Research

PAIN SEVERITY & IMPAIRMENT OF ACTIVITY BETWEEN PEGFILGRASTIM (P) AND FIXED DOSE FILGRASTIM (F) IN WOMEN WITH EARLY STAGE BREAST CANCER RECEIVING CHEMOTHERAPY

Objective: To compare the incidence & severity of muscle and/or joint pain (MJP) in patients (pts) receiving P (6mg SC for 1 day) or fixed-dose F (300mcg SC for 7-8 days).

Design: This is a prospective, observational study of women with breast cancer receiving chemotherapy and P or F. Pts were ineligible if they could not complete a pain diary, or had received P or F in the past 6 months. Baseline characteristics were assessed to identify risk factors for developing MJP. Each pt completed a pain diary to record MJP severity, its management & impact on everyday activities.

Results: 140 pts were enrolled. In both P & F groups, MJP peaked in prevalence & severity on days 3 to 6. Pain that increased ≥3 points were reported in 48% of pts. Daily activities were affected in 48% of reporting-days, with 26% reported as moderate or severe impairment. P was associated with lower muscle (p=0.0049) & joint (p=0.014) pain by regression analyses. Use of docetaxel was the sole baseline risk factor for developing MJP.

Conclusion: Pts on P or F experience significant MJP & impairment of daily activities but pts receiving P have less pain & burden relating to pain.

Contact Author
Mova Leung, Peel Regional Cancer Centre, Mississauga, ON

Co-authors
Tiffany Marr-Delmonte, Peel Regional Cancer Centre, Mississauga, ON
Jessica Kano, Peel Regional Cancer Centre, Mississauga, ON
Joy Eustaquio, Peel Regional Cancer Centre, Mississauga, ON
Brian Higgins, Peel Regional Cancer Centre, Mississauga, ON
Robert Myers, Peel Regional Cancer Centre, Mississauga, ON
Glenn Jone, Peel Regional Cancer Centre, Mississauga, ON